Naba Alsaha board recommends 50% bonus issue, 3% cash dividend for 2022

Logo of Naba Alsaha Medical Services Co.

Naba Alsaha Medical Services Co.'s board of directors recommended a 50% capital increase to SAR 105 million from SAR 70 million through distributing a 0.5 bonus share for each one share held, the company said in a statement to Tadawul today, March 29.

In a separate statement, the company said the board also recommended a 3% cash dividend for 2022, at SAR 0.3 per share.

Capital Increase Details
Current capital	SAR 70 mln
Number of shares	7 mln
Capital hike%	50% (one share for every two shares held)
Capital after increase	SAR 105 mln
Number of shares after increase	10.5 mln
Method of increase	Capitalizing SAR 35 mln from retained earnings
Record date	Shareholders of record who are registered with Edaa by the close of the second trading day following the record date
Objective	Supporting and financing the company's new expansion projects
Dividend Details (2022)
Current capital	SAR 70 mln
Number of shares	7 mln
Total dividend	SAR 2.1 mln
Percentage of capital	3% (SAR 0.3 a share)
Record date	Shareholders of record on the general meeting date that will be determined later, and those who are registered with Edaa by the close of the second trading day following the general meeting date
Payment date	To be determined later

*This is the first dividend for the company since its listing on Nomu-Parallel Market in September 2022.

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Most Read

Market Indices

Quotes

Popular Links

Quick Links

About Us

Join Us

Follow Us